{"name":"Hangzhou Highlightll Pharmaceutical Co., Ltd","slug":"hangzhou-highlightll-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TLL-018","genericName":"TLL-018","slug":"tll-018","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TLL-018 tablets","genericName":"TLL-018 tablets","slug":"tll-018-tablets","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"TLL-018","genericName":"TLL-018","slug":"tll-018","phase":"phase_3","mechanism":"TLL-018 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TLL-018 tablets","genericName":"TLL-018 tablets","slug":"tll-018-tablets","phase":"phase_3","mechanism":"TLL-018 tablets' mechanism of action is not publicly available.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOU3hfa0JPVU9zTXZWc1A0WkRUYVhLZlB3c1RPc1FxVU1mSFBlN0lQT0tOMHlvbXJwRlZMbFhxdV9zTkxfWXBkUFdGcWZaQkFRMHpNMWFvUGpTVjlHZzluYXp4QXI5TlJrT0NXR2JwMGFrd3hZeFdyUzVuR0NuZnVuSkEzdjRRUEFqWXhPUjhsRXBEeUFIZl9jLVc1VVoyaHRmWFRVTWw0S3pFOV9xMlYzU2RpR2ZEV1dieWpjRTd4eElFY2V6UkdhdWNOd0NUUXk1Um95SjhVNHRRRUxXNGtzc2d4a2NkcjN3YmlUWEZCWTlkc2U4YlNyMW50XzFzdw?oc=5","date":"2026-02-16","type":"trial","source":"Investing News Network","summary":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Investing News Network","headline":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPaVoxX0Fjd0RXMVFpM3hZM0ZUeU1SejhVNjY2Zk9VS0pKREtPa1Q1SEtPdE94d3dXR1pqTnBoTENtaXhtV3FrYTVEMU5WWVRsYVZWUGxzLVhJTV9tR0hKdGI3eFJxaUxvd244dEJWdzA4SS15dkVNdlBvSXlFWU0wTURvNndSRjZaRGMtZDdseE13MG5qUG1DUDB0b0R1UFVfNWZmdlR2N3YzU1BlV0FjcXpEbUNFakxkZ3c?oc=5","date":"2025-11-06","type":"pipeline","source":"BioWorld News","summary":"Hangzhou Raygene Pharmaceutical describes new benzotriazine dioxide compounds - BioWorld News","headline":"Hangzhou Raygene Pharmaceutical describes new benzotriazine dioxide compounds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxQSDZ5VXpadjBrYUpVNkpOT21abDZlUERXempURTc5NjRNS3J6Wl83cllyemx6NzNaMkxIWDJfS00tVXNvYl8xeTZnaXZDeVI2SFktcEZnRkRZQUg0alcwX2ttNEJGRUxtY21HWXNaVTJqWEdtQlNjLS16bWc4V2RZak9fRE9KRkhiYzhsbUI5bjd3dndERnlTcHJzc1ZvOUVsVHVRSDVoY1FMUG5tODM2dEJYTllkZzJqbVVJUVlRaTBCay1tMDFUY25wRGFXYnpKSmg4Nms2U3g0eUtKaDlzVGN3NWM1OGpuTGVSZzNJNGFPSUt1RVZTRWlKWkxyMlNsSW45YkpKMkhSOUZtUmNxSEt4LTNVOUxlZ19hdmJTdEFsTzdkRS1mVUs2RU1vUW1oUUxkWjVqMThlYjB6dWF4M2RMYktMVlA0MHdUQw?oc=5","date":"2025-02-20","type":"pipeline","source":"GlobeNewswire","summary":"Chronic Spontaneous Urticaria Market to Register - GlobeNewswire","headline":"Chronic Spontaneous Urticaria Market to Register","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxOdERkUXowYm91d0VKWWo0SlBSWktzaGZwM3RJdm9kV0t1ZnhpZUFiVENMRmdJOWtUNXV6WmJZMEpBN3Q1X2d2TXFXOEEzNTZhRjd0N2E4Z1paRnVPenBtNllvT2JmbjBndUdTNGNpam83OGRrZDlGdVVNMWp0dHZ4SHRKb3hXMzBzN3Qxd01XQ1pmYVpDbkFpSWRaVGc4YUI0alViSW1xYjUzNXJDd3FwUlJRRktEdDVmU1BwYzJQNUpCYlVpbDdjeDVyMEMwYUlBUVZsZW1jSkRYMVhxMUU0UVN4R1luNDlfRVoxLWRDWm9NV3R5WTByRlRLTTNKeldweUhUSzNfZUs?oc=5","date":"2024-11-04","type":"trial","source":"GlobeNewswire","summary":"Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire","headline":"Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPTlFzbTEzcGlzY1FGcEpTYk9Nc0JoQ2JldThSUHdNNmVQTjFDY3VhSEw1Q3lSWnNvak1abWpfamtLWllmT2EtWFlqTnFiRTE1c19iLUdZclVpWEtka3g4VC16eWllSHZnRTlWNXp4VDgwWjF3cUJab0FndDhBNV9vQlZHSVRNbExUaHpuQXJrMWk5cy02T3hVNXJyTUdIVmQ0dHd2TXNlQmhVZEdsRGtTOHRRQjdGZXhXZ1dRYw?oc=5","date":"2023-03-28","type":"deal","source":"BioWorld News","summary":"Biohaven acquires early stage TYK2/JAK1 inhibitor from Highlightll in $970M deal - BioWorld News","headline":"Biohaven acquires early stage TYK2/JAK1 inhibitor from Highlightll in $970M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOQ24zZ282TU1GYUJPdm9jUnBzT0VheXZqZG5vOFZjWmFDTVJNOVpVWjRTRTF5RXk5Njd3UWVxYlBaQ3FRTm40aDFjS29FYjhqdHhUT1JmdjA4b1JlNXBUUHFxOUlGcVgwVzVJTmQtUVJFaDc5MVMzNEZETGpWTXJMVkdwRGNmcTNHZXZJaGxkUEdKUURI?oc=5","date":"2023-03-22","type":"deal","source":"BioPharma Dive","summary":"Biohaven strikes a deal to take TYK2 drugs in a new direction - BioPharma Dive","headline":"Biohaven strikes a deal to take TYK2 drugs in a new direction","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}